All patients
Age < 65y (younger) Age > 65y Asian type cell type, non squamous cell cell type, squamous cell ECOG 0 ECOG 1 EGFR mutant Gender, female Gender, male PDL1 (TC0 and IC0 : <1% of TC and IC) PDL1 (TC1/2/3 or IC1/2/3 : ≥1% of TC or IC) PDL1 (TC3 or IC3 : ≥50% of TC or ≥10% of IC ) PDL1 < 25% PDL1 >25% smoker (current or former) smoker (never) stage IIIa stage IIIb
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
lung cancer : non small cell (NSCLC), durvalumab based treatment vs. chemotherapy, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.63 [0.42; 0.94]
MYSTIC (D ; all population), 2020 0.96 [0.81; 1.13]
MYSTIC (D ; PDL1>25%), 2020 0.76 [0.56; 1.03]
0.81 [0.64 ; 1.03 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020 3 57% 1,197 moderate not evaluable progression or deaths (PFS)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.71 [0.49; 1.03]
MYSTIC (D ; PDL1>25%), 2020 0.87 [0.59; 1.29]
0.78 [0.60 ; 1.03 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, MYSTIC (D ; PDL1>25%), 2020 2 0% 451 moderate not evaluable objective responses (ORR)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 3.87 [1.55; 9.69]
MYSTIC (D ; PDL1>25%), 2020 0.91 [0.58; 1.43]
1.77 [0.43 ; 7.29 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, MYSTIC (D ; PDL1>25%), 2020 2 87% 451 moderate not evaluable AE (any grade)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.24 [0.01; 5.43]
MYSTIC (D ; all population), 2020 0.59 [0.31; 1.13]
MYSTIC (D ; PDL1>25%), 2020 0.42 [0.14; 1.22]
0.52 [0.30 ; 0.90 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020 3 0% 1,160 moderate not evaluable AE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.36 [0.18; 0.75]
MYSTIC (D ; all population), 2020 0.81 [0.60; 1.10]
MYSTIC (D ; PDL1>25%), 2020 0.91 [0.58; 1.41]
0.71 [0.47 ; 1.08 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020 3 58% 1,160 moderate not evaluable AE leading to death (grade 5)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 3.27 [0.63; 16.86]
MYSTIC (D ; all population), 2020 0.82 [0.38; 1.75]
MYSTIC (D ; PDL1>25%), 2020 0.75 [0.20; 2.86]
1.02 [0.50 ; 2.09 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020 3 18% 1,160 moderate not evaluable AE leading to treatment discontinuation (any grade)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.63 [0.24; 1.67]
MYSTIC (D ; all population), 2020 0.72 [0.47; 1.12]
MYSTIC (D ; PDL1>25%), 2020 0.75 [0.38; 1.46]
0.72 [0.51 ; 1.01 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020 3 0% 1,160 moderate not evaluable AE leading to treatment discontinuation (grade 3-4)detailed results MYSTIC (D ; all population), 2020 1.10 [0.64; 1.89]
1.10 [0.64 ; 1.89 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable SAE (any grade)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.73 [0.81; 3.73]
MYSTIC (D ; PDL1>25%), 2020 1.22 [0.77; 1.94]
1.34 [0.90 ; 1.99 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, MYSTIC (D ; PDL1>25%), 2020 2 0% 439 moderate not evaluable STRAE (any grade)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.02 [0.33; 3.10]
MYSTIC (D ; all population), 2020 0.56 [0.35; 0.90]
MYSTIC (D ; PDL1>25%), 2020 0.38 [0.18; 0.77]
0.54 [0.36 ; 0.81 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020 3 11% 1,160 moderate not evaluable STRAE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 0.48 [0.28; 0.84]
0.48 [0.28 ; 0.84 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable TRAE (any grade)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.19 [0.08; 0.46]
MYSTIC (D ; all population), 2020 0.24 [0.17; 0.34]
MYSTIC (D ; PDL1>25%), 2020 0.21 [0.12; 0.38]
0.23 [0.17 ; 0.30 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020 3 0% 1,160 moderate not evaluable TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.13 [0.05; 0.36]
MYSTIC (D ; all population), 2020 0.34 [0.24; 0.49]
MYSTIC (D ; PDL1>25%), 2020 0.36 [0.22; 0.61]
0.30 [0.20 ; 0.46 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020 3 41% 1,160 moderate not evaluable TRAE leading to death (grade 5)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.02 [0.02; 52.03]
MYSTIC (D ; all population), 2020 0.63 [0.11; 3.82]
MYSTIC (D ; PDL1>25%), 2020 0.95 [0.06; 15.32]
0.75 [0.18 ; 3.05 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020 3 0% 1,160 moderate not evaluable TRAE leading to discontinuation (any grade)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.02 [0.24; 4.26]
MYSTIC (D ; all population), 2020 0.55 [0.31; 0.99]
MYSTIC (D ; PDL1>25%), 2020 0.47 [0.21; 1.04]
0.56 [0.36 ; 0.87 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020 3 0% 1,160 moderate not evaluable TRAE leading to discontinuation (grade 3-4)detailed results MYSTIC (D ; all population), 2020 1.28 [0.60; 2.75]
1.28 [0.60 ; 2.75 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable Acute kidney injury TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 2.05 [0.07; 62.21]
2.05 [0.07 ; 62.21 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1 0% 125 NA not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 2.05 [0.07; 62.21]
MYSTIC (D ; all population), 2020 1.91 [0.06; 57.12]
1.98 [0.18 ; 21.98 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, MYSTIC (D ; all population), 2020 2 0% 846 moderate not evaluable Alopecia TRAE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 0.95 [0.02; 48.21]
0.95 [0.02 ; 48.21 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable Anaemia TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.08 [0.00; 1.41]
MYSTIC (D ; all population), 2020 0.01 [0.00; 0.19]
0.03 [0.00 ; 0.22 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, MYSTIC (D ; all population), 2020 2 0% 846 moderate not evaluable Asthenia TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.25 [0.01; 5.61]
MYSTIC (D ; all population), 2020 0.12 [0.01; 0.94]
0.15 [0.03 ; 0.83 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, MYSTIC (D ; all population), 2020 2 0% 846 moderate not evaluable Colitis TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 2.05 [0.07; 62.21]
MYSTIC (D ; all population), 2020 1.91 [0.06; 57.12]
1.98 [0.18 ; 21.98 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, MYSTIC (D ; all population), 2020 2 0% 846 moderate not evaluable Constipation TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.50 [0.02; 15.30]
MYSTIC (D ; all population), 2020 0.48 [0.02; 14.24]
0.49 [0.04 ; 5.44 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, MYSTIC (D ; all population), 2020 2 0% 846 moderate not evaluable Decreased appetite TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.50 [0.02; 15.30]
MYSTIC (D ; all population), 2020 0.24 [0.03; 2.13]
0.30 [0.05 ; 1.87 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, MYSTIC (D ; all population), 2020 2 0% 846 moderate not evaluable Dermatitis acneiform TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.50 [0.02; 15.30]
0.50 [0.02 ; 15.30 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1 0% 125 NA not evaluable Diabetes TRAE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 0.95 [0.02; 48.21]
0.95 [0.02 ; 48.21 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.02 [0.02; 52.03]
MYSTIC (D ; all population), 2020 0.95 [0.13; 6.81]
0.97 [0.17 ; 5.60 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, MYSTIC (D ; all population), 2020 2 0% 846 moderate not evaluable Dyspepsia TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.50 [0.02; 15.30]
0.50 [0.02 ; 15.30 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1 0% 125 NA not evaluable Fatigue TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.02 [0.02; 52.03]
MYSTIC (D ; all population), 2020 0.81 [0.27; 2.45]
0.83 [0.29 ; 2.39 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, MYSTIC (D ; all population), 2020 2 0% 846 moderate not evaluable Febrile neutropenia TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.08 [0.00; 1.41]
0.08 [0.00 ; 1.41 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1 0% 125 NA not evaluable Hepatitis TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 2.05 [0.07; 62.21]
MYSTIC (D ; all population), 2020 1.91 [0.06; 57.12]
1.98 [0.18 ; 21.98 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, MYSTIC (D ; all population), 2020 2 0% 846 moderate not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.02 [0.02; 52.03]
MYSTIC (D ; all population), 2020 0.95 [0.02; 48.21]
0.98 [0.06 ; 15.84 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, MYSTIC (D ; all population), 2020 2 0% 846 moderate not evaluable Hypophysitis TRAE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 0.95 [0.02; 48.21]
0.95 [0.02 ; 48.21 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable Hypothyroidism TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.02 [0.02; 52.03]
MYSTIC (D ; all population), 2020 3.83 [0.17; 85.25]
2.30 [0.20 ; 26.34 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, MYSTIC (D ; all population), 2020 2 0% 846 moderate not evaluable Increased lipase level TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 2.05 [0.07; 62.21]
2.05 [0.07 ; 62.21 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1 0% 125 NA not evaluable Infusion-related reactions TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.02 [0.02; 52.03]
1.02 [0.02 ; 52.03 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1 0% 125 NA not evaluable Leucopenia TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.16 [0.01; 3.32]
0.16 [0.01 ; 3.32 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1 0% 125 NA not evaluable Nausea TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.25 [0.01; 5.61]
MYSTIC (D ; all population), 2020 0.08 [0.00; 1.41]
0.13 [0.02 ; 1.11 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, MYSTIC (D ; all population), 2020 2 0% 846 moderate not evaluable Nephritis TRAE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 0.95 [0.02; 48.21]
0.95 [0.02 ; 48.21 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable Neutropenia TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.09 [0.01; 1.76]
MYSTIC (D ; all population), 2020 0.02 [0.00; 0.18]
0.04 [0.01 ; 0.20 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, MYSTIC (D ; all population), 2020 2 0% 846 moderate not evaluable Pneumonia TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.02 [0.06; 16.62]
1.02 [0.06 ; 16.62 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1 0% 125 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.02 [0.02; 52.03]
MYSTIC (D ; all population), 2020 3.85 [0.43; 34.59]
2.80 [0.41 ; 19.09 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, MYSTIC (D ; all population), 2020 2 0% 846 moderate not evaluable Pruritus TRAE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 0.95 [0.02; 48.21]
0.95 [0.02 ; 48.21 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable Rash TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.02 [0.06; 16.62]
MYSTIC (D ; all population), 2020 2.88 [0.30; 27.79]
1.90 [0.33 ; 11.07 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, MYSTIC (D ; all population), 2020 2 0% 846 moderate not evaluable Stomatitis TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 2.05 [0.07; 62.21]
2.05 [0.07 ; 62.21 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1 0% 125 NA not evaluable Thrombocytopenia TRAE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 0.03 [0.00; 0.42]
0.03 [0.00 ; 0.42 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable Vomiting TRAE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 0.07 [0.00; 1.18]
0.07 [0.00 ; 1.18 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable Alopecia AE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 0.95 [0.02; 48.21]
0.95 [0.02 ; 48.21 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable Anaemia AE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 0.16 [0.07; 0.34]
0.16 [0.07 ; 0.34 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable Asthenia AE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 0.95 [0.41; 2.23]
0.95 [0.41 ; 2.23 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable Back pain AE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 0.32 [0.03; 3.05]
0.32 [0.03 ; 3.05 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable Constipation AE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 0.95 [0.06; 15.31]
0.95 [0.06 ; 15.31 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable Cough AE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 1.91 [0.06; 57.12]
1.91 [0.06 ; 57.12 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable Decreased appetite AE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 1.44 [0.40; 5.14]
1.44 [0.40 ; 5.14 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable Diarrhoea AE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 0.38 [0.07; 1.96]
0.38 [0.07 ; 1.96 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable Dyspnoea AE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 1.61 [0.58; 4.47]
1.61 [0.58 ; 4.47 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable Fatigue AE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 1.20 [0.47; 3.07]
1.20 [0.47 ; 3.07 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable Nausea AE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 0.16 [0.02; 1.31]
0.16 [0.02 ; 1.31 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable Neutropenia AE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 0.07 [0.02; 0.24]
0.07 [0.02 ; 0.24 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable Pruritus AE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 0.95 [0.02; 48.21]
0.95 [0.02 ; 48.21 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable Pyrexia AE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 5.76 [0.29; 115.45]
5.76 [0.29 ; 115.45 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable Rash AE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 2.88 [0.30; 27.79]
2.88 [0.30 ; 27.79 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable Thrombocytopenia AE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 0.05 [0.01; 0.38]
0.05 [0.01 ; 0.38 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable Vomiting AE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 0.54 [0.16; 1.86]
0.54 [0.16 ; 1.86 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable Weight decreased AE (grade 3-4)detailed results MYSTIC (D ; all population), 2020 2.88 [0.30; 27.79]
2.88 [0.30 ; 27.79 ] MYSTIC (D ; all population), 2020 1 0% 721 NA not evaluable 0.0 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-09-29 01:39 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 161,226,41,225,182,198,179,200,195,254,242,243,199,190,229,266,191,196,36,228,174,171,173,307,165,163,176,308,164,166,220,197,255,37,245,204,244,241,227,217,177,279,167,1,170,261,280,168,169,335,334
- treatments: 854,374,953,672,1080,1560,1073,862
